Immunocytokine combination therapy
US10195253B2 · kind B2 · utility
2Cited by
1References
17Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jun 29, 2012 |
| Grant date | Feb 5, 2019 |
| Priority date | — |
| Expiry date | Oct 8, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/33
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods and compositions for treating tumors, especially skin tumors, by locally administering single doses of tumor necrosis factor alpha (TNFα) and interleukin-2 (IL2) at the tumor site, where the TNFα and IL2 are delivered as immunoconjugates comprising an antibody targeted to a splice isoform of an extracellular matrix component such as fibronectin.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.